Table 1 Baseline characteristics of the patients at an initial diagnosis of metastasis.
Pre new drug era | Post new drug era | p | ||
|---|---|---|---|---|
(N = 78) | (N = 80) | |||
Median age, years (range) | 69.5 (38–88) | 75.5 (48–87) | < 0.001 | |
Median follow up period, months (range) | 12.7 (1.18–85.5) | 14.5 (0–127) | 0.25 | |
Sex, N | Male | 61 | 57 | 0.36 |
Female | 17 | 23 | ||
Median BMI, kg/m2 (range) | 21.3 (14.9–28.7) | 22.8 (14.9–32.8) | 0.24 | |
PS, N | 0 | 28 | 28 | 0.69 |
1 | 35 | 34 | ||
2 | 14 | 14 | ||
3 | 1 | 4 | ||
CCI, N | 0 | 33 | 38 | 0.63 |
1 | 28 | 22 | ||
2 | 14 | 13 | ||
3 | 2 | 5 | ||
4 | 1 | 2 | ||
Median serum albumin, g/dL (range) | 4.0 (2.2–5.1) | 3.8 (2.2–4.7) | < 0.01 | |
Median CRP, mg/dL (range) | 0.49 (0.01–13.9) | 0.56 (0.02–15.9) | 0.34 | |
Median eGFR, mL/min/1.73m2 (range) | 53.7 (20.9–135.2) | 48.9 (5.43–111.3) | < 0.05 | |
Median Hb, g/dL (range) | 11.9 (7.6–16.6) | 12.2 (7.6–15.5) | 0.52 | |
Tumor location, N | BC | 34 | 38 | 0.64 |
UTUC | 44 | 42 | ||
Presence of variant histology or non-UC, N | 19 | 20 | 1.00 | |
Cisplatin administration, N | 52 | 53 | 1.00 | |
History of radical surgery, N | 46 | 36 | 0.08 | |
Initial metastatic site, N | Regional lymph node | 38 | 49 | 0.15 |
Distant lymph node | 22 | 23 | 1.00 | |
Visceral | 42 | 34 | 0.20 | |
Liver | 9 | 9 | 1.00 | |
Lung | 22 | 14 | 0.13 | |
Bone | 18 | 15 | 0.56 | |
Others | 16 | 23 | 0.27 | |
Number of initial metastatic site, N | 1 | 45 | 42 | 0.58 |
2 | 23 | 27 | ||
3 | 7 | 5 | ||
> = 4 | 3 | 6 | ||
